Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Adebrelimab by Jiangsu Hengrui Medicine for Esophageal Squamous Cell Carcinoma (ESCC): Likelihood of Approval
Adebrelimab is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Esophageal Squamous Cell Carcinoma (ESCC)....
Adebrelimab by Jiangsu Hengrui Medicine for Cervical Cancer: Likelihood of Approval
Adebrelimab is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Cervical Cancer. According to GlobalData,...
Adebrelimab by Jiangsu Hengrui Medicine for Advanced Malignancy: Likelihood of Approval
Adebrelimab is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Advanced Malignancy. According to GlobalData,...
Adebrelimab by Jiangsu Hengrui Medicine for Pancreatic Cancer: Likelihood of Approval
Adebrelimab is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Pancreatic Cancer. According to GlobalData,...
Adebrelimab by Jiangsu Hengrui Medicine for Small-Cell Lung Cancer: Likelihood of Approval
Adebrelimab is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Small-Cell Lung Cancer. According to...
Adebrelimab by Jiangsu Hengrui Medicine for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval
Adebrelimab is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Bile Duct Cancer (Cholangiocarcinoma). According...
Adebrelimab by Jiangsu Hengrui Medicine for Nasopharyngeal Cancer: Likelihood of Approval
Adebrelimab is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Nasopharyngeal Cancer. According to GlobalData,...
Adebrelimab by Jiangsu Hengrui Medicine for Hepatocellular Carcinoma: Likelihood of Approval
Adebrelimab is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Hepatocellular Carcinoma. According to GlobalData,...